Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation with Insulin Resistance, Inflammation, and Liver Histology

Journal of Investigative Medicine

Volumn 63, Issue 7, 2015, Pages 871-877

  Boga, Salih ^a   Alkim, Huseyin ^a   Koksal, Ali Riza ^a   Bayram, Mehmet ^a   Ozguven, Muveddet Banu Yilmaz ^b   Ergun, Meltem ^a   Neijmann, Sebnem Tekin ^c   Ozgon, Gulay ^d   Alkim, Canan ^a  

^a YALE UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Pediatric Surgery   (Turkey)

^c BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d Nesiller Genetics Diagnostic Lab   (Turkey)

Author keywords

asymmetric dimethylarginine; HOMA IR; hs CRP; IL 6; NAFLD

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; N(G),N(G) DIMETHYLARGININE; ARGININE; N,N-DIMETHYLARGININE;

ARTICLE; BODY COMPOSITION; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INSULIN RESISTANCE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; ADULT; ANALOGS AND DERIVATIVES; BLOOD; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ARGININE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84943151832     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1097/JIM.0000000000000230     Document Type: Article

References (38)

1. Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis. 2012;30(2):158-162.
2. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234-238.
3. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49(4): 608-612.
4. Siervo M, Corander M, Stranges S, et al. Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of asymmetric dimethylarginine (ADMA). Nutr Metab CardiovascDis. 2011; 21(1):1-10.
5. Vallance P, Leone A, Calver A, et al. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20(Suppl 12):S60-S62.
6. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
7. Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851(1-2):42-50.
8. Kielstein JT, Böger RH, Bode-Böger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10(3):594-600.
9. Wilson AM, Shin DS, Weatherby C, et al. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med. 2010;15(4):267-274.
10. Cavusoglu E, Ruwende C, Chopra V, et al. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis. 2010;210(1):226-231.
11. Sydow K, Mondon CE, Cooke JP. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med. 2005;10(Suppl 1):S35-S43.
12. Richir MC, Bouwman RH, Teerlink T, et al. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. JPEN J Parenter Enteral Nutr. 2008;32(6):613-621.
13. Tsikas D, Rode I, Becker T, et al. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease. Hepatology. 2003;38(4):1063-1064.
14. Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 2001;88(10):1201-1203.
15. Altinova AE, Arslan M, Sepici-Dincel A, et al. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin EndocrinolMetab. 2007;92(5):1881-1885.
16. Videla LA, Rodrigo R, Orellana M, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond). 2004;106(3):261-268.
17. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103(6):1372-1379.
18. ACE/ADATask Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control. Diabetes Care. 2006;29(8):1955-1962.
19. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-438.
20. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-1321.
21. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339(8793):572-575.
22. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005;97(5):e53-e59.
23. Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358(9299):2113-2117.
24. Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003;59(4):824-833.
25. Colak Y, Senates E, Yesil A, et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine. 2013;43(1):100-107.
26. Kasumov T, Edmison JM, Dasarathy S, et al. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism. 2011;60(6):776-781.
27. Lluch P, Torondel B, Medina P, et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol. 2004;41(1):55-59.
28. Vizzutti F, Romanelli RG, Arena U, et al. ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest. 2007;37(6):509-515.
29. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;2877(11):1420-1426.
30. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia. 2002;45(12):1609-1616.
31. Garcia RG, Perez M, Maas R, et al. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol. 2007;122(2):176-178.
32. Onat A, Hergenç G, Can G, et al. Serum asymmetric dimethylarginine levels among Turks: association with metabolic syndrome in women and tendency to decrease in smokers. Turk Kardiyol Dern Ars. 2008;36(1):7-13.
33. Lundman P, Eriksson MJ, Stühlinger M, et al. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol. 2001;38(1):111-116.
34. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99(24):3092-3095.
35. Böger RH, Lentz SR, Bode-Böger SM, et al. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond). 2001;100(2):161-167.
36. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 1999;33(4):652-658.
37. Tripepi G, Mattace Raso F, Sijbrands E, et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol. 2011;6(7):1714-1721.
38. Kukla M, Zwirska-Korczala K, Hartleb M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010;45(2):235-242.